Navigation Links
Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3
Date:11/14/2007

VANCOUVER, Nov. 14 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG; BBSE: DRP) today announced its financial results for the three and nine months ended September 30, 2007, showing strong growth in sales and profits for its core antibiotic business. Meanwhile, the Company also announced the sale of its EPO operation to an unaffiliated party through a separate press release.

Highlights for the three and nine months ended September 30, 2007

-----------------------------------------------------------------

- Sales for the third quarter increased 102% to $23.10 million from

$11.41 million for the same period of 2006. Sales for the first nine

months reached $59.98 million, with an increase of 60% as compared to

the same period of 2006;

- Gross profit and gross margin for the third quarter were

$4.31 million and 18.66% compared to $0.73 million and 6.38% for the

same period of 2006;

- Operating income increased 347% to $1.31 million for this quarter

from a net loss of $0.53 million for same period of 2006;

- Net cash inflow generated from operating activities for the quarter

was $2.08 million, as compared to a net cash outflow of $1.23 million

for same period of 2006;

- Net income from continuing operations for the third quarter amounted

to $0.97 million, up 200% from a net loss of $0.97 million for the

same period of 2006;

- A net loss of $2.57 million was shown from discontinuing operations,

which was due to the impact of a $2.64 million non-cash impairment

charge of intangible assets and goodwill related to EPO disposal.

As the result of the EPO disposal, the Company will be focusing on core antibiotic business with vertical product lines covering intermediates, active pharmaceutical ingredients and formulation drugs, which all grew strongly over the last quarters.

The sale momentum from Chemical Division that contains intermediates and API products actually started from the fourth quarter of last year, and continued through all three quarters of this year. As one of dominating producers of 7ACA, the Company further strengthened its market position and delivered 183% year-over-year revenue growth in Chinese market during the third quarter of 2007. Mainly driven by strong market demand, the Company realized 138 tons of sales in the third quarter, which was 99% of 140 tons of total production output. Meanwhile, the Company successfully increased its sales by 84% in China and by 66% in the international market for Clavulanic Acid, reflecting the strong market acceptance of our high production quality. Under the favorable market conditions, the Company realized a utilization rate of 93% for 7ACA and 80% for Clavulanic Acid. The higher facility utilization, combined with our continuous efforts in technology improvement, led to lowering of our per unit production costs. As a result, the Chemical Division's gross margin increased to 27.57% in this quarter from 10.68% for the same period of 2006. Moreover, as previously disclosed, the Company has successfully established a new production line producing 7ACA using the biotech method, adding an additional annual production capacity of 120 tons 7ACA. Management believes that the increased capacity will enable the Company to promptly respond to the strong customer demand and gain further market share.

The Company also achieved substantial sales increase and improved gross margin for the Pharma Division that contains formulation business as the Company further expanded its market share in the Chinese market. During the third quarter, the sales increased by 266% to $5.59 million as compared to the same period of 2006, accounting for 24% of the total revenues of the Company. The total sales quantity reached 33 million units as compared to 20 million units in the second quarter and 15 million units in the first quarter of 2007.

Mainly due to the significant revenue growth, improved productivity and increased gross margins for all our products, net income from continuing operations for the third quarter increased 200% to $0.97 million from a net loss of $0.97 million for the same period of 2006. Net income from continuing operations for the nine months amounted to $2.12 million as compared to a net loss of $0.86 million for the same quarter of 2006. The net cash inflow generated from operating activities amounted to $2.08 million, which provided the Company greater flexibility to expand the operations in its core business. Meanwhile, due to the impact of a $2.64 million non-cash impairment charge of intangible assets and goodwill related to EPO disposal as disclosed in the separate press release dated November 14, 2007, the Company had a net loss of $1.61 million for the third quarter, which was the net of $0.97 million net income from continuing operations and $2.57 million net loss from discontinuing operations.

"The solid performance of our core antibiotic operation once again demonstrates the strength of our business model and our ability to achieve growth in revenues, profitability and cashflow," said Mr. Yanlin Han, Chairman and CEO of the Company. "We are focusing our efforts in the antibiotic market which we intend to lead while showing a sustainable and growing profit. In addition, the Company is also actively exploring additional business opportunities in broadening its core antibiotic product offerings and increasing production capacities. We are confident that the benefits of all these initiatives will be reflected in the Company's performance in the future."

This press release contains forward looking statements, including but not limited to, that the Company will continue to experience growth in sales of its main products, that it will continue to be able to improve its product quality and efficiency, that it will continue to achieve continuous growth in business and profitability in the near future. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward looking statements. Readers should not place undue reliance on forward looking statements, which only reflect the views of management as of the date hereof. The Company does not undertake the obligation to publicly revise these forward looking statements to reflect subsequent events or circumstances. Readers should carefully review the risk factors and other factors described in its periodic reports filed with the Securities and Exchange Commission.

CONTACT: Dragon Pharmaceutical Inc., Maggie Deng, Telephone: (604) 669-8817; or North America Toll Free: 1-877-388-3784, Email: irdragon@dragonpharma.com, Website: http://www.dragonpharma.com


'/>"/>
SOURCE Dragon Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved
2. CCF Reviews Contents of SCHIP Reauthorization Bill Legislation Places SCHIP on Solid Path
3. Akela Pharma Inc. Completes Share Consolidation
4. Cosmetic Bootcamp Solidifies Lead as Investor Symposium for Aesthetic Medicine
5. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
6. Nurses From Across Nation Join Solidarity Caravan in Support of Striking Kentucky RNs
7. Smoking may strongly increase long-term risk of eye disease
8. Diabetes appears to increase risk of death for patients with acute coronary syndromes
9. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
10. Fat on chest and upper back increases risk of insulin resistance
11. Ability to cope with stress can increase good cholesterol in older white men, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Engineers at ... bio-compatible, because it produces the same kind of electrical energy that the body uses. ... form of moving electrons. This flow of electrons out of the battery is generated ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... federal Substance Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted Response to ... Department of Health Care Services, will facilitate the development of a hub and ...
(Date:7/24/2017)... ... July 24, 2017 , ... Every year, thousands of dedicated Higher ... InstructureCon. Each annual event is coupled with a dynamic theme like Camp Canvas; this ... theme, Mission: InstructureCon 0017. , To extend their partnership with Canvas beyond the ...
(Date:7/24/2017)... Beach, California (PRWEB) , ... July 24, 2017 ... ... commercialization of autologous fat (adipose) transfer systems announces the issuance of United States ... ‘324 patent) for its adipose filtration technology. The '398 and '324 patents ...
(Date:7/24/2017)... ... July 24, 2017 , ... Paul Vitenas, MD, FACS is excited to report ... invited to attend Allergan’s recent meeting with their Plastics Advisory Board. As one of ... Allergan is bringing a newly defined structure to the aesthetics market. Dr. Vitenas ...
Breaking Medicine News(10 mins):
(Date:7/17/2017)... 17, 2017  MedX Holdings, Inc., the manufacturer and ... and rehabilitation equipment, today announced the national roll out ... considered the gold standard for the treatment of low ... strengthening equipment. How ... physician or practice who prescribe the MedX Home Back ...
(Date:7/13/2017)... 13, 2017  Centurion Medical Products, a leader in medical product ... fecal impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part ... alleviate patient pain while preventing unneeded emergency department admission due to ...
(Date:7/12/2017)... INDIANAPOLIS , July 12, 2017  Eli Lilly and ... settlement agreement with generic companies to resolve pending patent litigation ... Virginia regarding the Cialis ® ... expire on April 26, 2020. As part of the agreement, ... on September 27, 2018. "The unit dose patent ...
Breaking Medicine Technology: